Zura Bio Ltd (ZURA) Stock Price, Quote & News

Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33...

Industry: Biotechnology

Sector: Healthcare

Phone: 702 825 9872

Website: zurabio.com

Address:

1489 W. Warm Springs Road, Suite 110, Henderson, United States

MikeCaymanTrades Jun. 27 at 8:41 PM

$ZURA break from the long term trendline down. Overbought now but the weekly chart starting to turn up.

0 · Reply

StockScanners Jun. 27 at 5:56 PM

$ZURA keep watch if this holds above 5.19

0 · Reply

SannieVerraderlijk Jun. 27 at 10:44 AM

$ZURA Recent interview with CEO Sandeep Kulkarni. Readouts confirmed: HS Q4 26, SSC H1 27 https://www.youtube.com/watch?v=oKzZHBH_hfo

0 · Reply

topstockalerts Jun. 26 at 8:04 PM

$ZURA this is one of the cleaner charts on my screen today

0 · Reply

BanditQ Jun. 26 at 7:27 PM

$ZURA sold everything. +20% gain. Q4 is still a long way. Pretty sure we'll have another buying opportunity

0 · Reply

BanditQ Jun. 26 at 6:53 PM

$ZURA beautiful textbook chart

0 · Reply

deniz100 Jun. 26 at 4:37 PM

$ZURA Weak hand shake out. Loaded heavy above $4. Double digits will print here

0 · Reply

itrekntravel Jun. 26 at 3:42 PM

$ZURA hit my scans this am. what's moving it ~ anyone know?

1 · Reply

SannieVerraderlijk Jun. 26 at 3:15 PM

$ZURA

0 · Reply

BanditQ Jun. 26 at 2:45 PM

$ZURA hell yeah

0 · Reply

Zura Bio Slides: Corporate presentation

May 22, 2026, 8:00 AM EDT - 5 weeks ago

Zura Bio Proxy statement: Proxy filing

May 14, 2026, 7:30 AM EDT - 6 weeks ago

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-05-13T12:19:46.000Z - 6 weeks ago

Zura Bio names Muzammil Mustufa chief business officer

May 13, 2026, 7:30 AM EDT - 6 weeks ago

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

2026-05-07T14:42:59.000Z - 7 weeks ago

Zura Bio reports Q1 EPS (22c) vs (19c) last year

May 7, 2026, 7:30 AM EDT - 7 weeks ago

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Zura Bio Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Zura Bio Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

Zura Bio Slides: Corporate presentation

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Zura Bio Proxy statement: Proxy filing

Apr 22, 2026, 7:00 AM EDT - 2 months ago

Zura Bio Slides: Corporate presentation

2026-04-16T16:15:53.000Z - 2 months ago

Zura Bio management to meet virtually with Clear Street

2026-03-23T20:25:55.000Z - 3 months ago

Zura Bio management to meet with Piper Sandler

2026-03-20T11:41:41.000Z - 3 months ago

Zura Bio price target lowered to $15 from $16 at Oppenheimer

2026-03-19T20:16:13.000Z - 3 months ago

Zura Bio reports FY25 EPS ($1.06) vs (60c) last year

Mar 19, 2026, 4:05 PM EDT - 3 months ago

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Zura Bio Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 3 months ago

Zura Bio Earnings release: Q4 2025

Mar 10, 2026, 2:20 PM EDT - 3 months ago

Zura Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 7:00 AM EDT - 3 months ago

Zura Bio Slides: Corporate presentation

Mar 5, 2026, 6:30 AM EST - 4 months ago

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress

Mar 2, 2026, 6:30 AM EST - 4 months ago

Zura Bio to Participate in Upcoming Investor Conferences

Feb 27, 2026, 6:30 AM EST - 4 months ago

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

2026-02-25T12:39:16.000Z - 4 months ago

Zura Bio 18.2M share Spot Secondary priced at $6.25

Feb 25, 2026, 6:30 AM EST - 4 months ago

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

2026-02-24T22:02:41.000Z - 4 months ago

Zura Bio announces common stock offering, amount not stated

2026-02-24T22:02:21.000Z - 4 months ago

Zura Bio spot secondary offering; price range $6.00-$6.25

Feb 24, 2026, 4:01 PM EST - 4 months ago

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

Feb 23, 2026, 6:30 AM EST - 4 months ago

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.

2026-02-19T13:44:25.000Z - 4 months ago

Zura Bio management to meet with Piper Sandler

Feb 11, 2026, 11:00 AM EST - 4 months ago

Zura Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 11, 2026, 7:00 AM EST - 4 months ago

Zura Bio Slides: Corporate presentation

2026-02-09T12:45:59.000Z - 4 months ago

Wedbush bullish on Zura Bio, initiates with an Outperform

2026-02-09T11:36:09.000Z - 4 months ago

Zura Bio initiated with an Outperform at Wedbush

Feb 4, 2026, 6:30 AM EST - 5 months ago

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit

2026-01-21T13:55:23.000Z - 5 months ago

Zura Bio CEO Robert Lisicki resigns, Sandeep Kulkarni succeeds

Jan 21, 2026, 8:50 AM EST - 5 months ago

Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

2026-01-12T11:40:55.000Z - 5 months ago

Zura Bio provides business updates, 2026 outlook

Jan 12, 2026, 6:30 AM EST - 5 months ago

Zura Bio Reports Business Updates and Outlook for 2026

Nov 13, 2025, 7:00 AM EST - 8 months ago

Zura Bio Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 8 months ago

Zura Bio Quarterly report: Q3 2025

2025-11-13T11:40:53.000Z - 8 months ago

Zura Bio reports Q3 EPS (21c), consensus (18c)

Nov 13, 2025, 6:30 AM EST - 8 months ago

Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates

2025-11-12T22:25:31.000Z - 8 months ago

Zura Bio initiated with a Buy at Clear Street

Sep 4, 2025, 2:45 PM EDT - 10 months ago

Zura Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 2, 2025, 6:00 PM EDT - 10 months ago

Zura Bio Slides: Corporate Presentation

Aug 20, 2025, 6:30 AM EDT - 11 months ago

Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference

2025-08-19T10:15:21.000Z - 11 months ago

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

2025-08-15T11:45:28.000Z - 11 months ago

Zura Bio price target lowered to $16 from $17 at Oppenheimer

Aug 14, 2025, 8:15 AM EDT - 11 months ago

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Zura Bio Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Zura Bio Earnings release: Q2 2025

Jul 17, 2025, 4:30 PM EDT - 1 year ago

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 1, 2025, 6:30 AM EDT - 1 year ago

Zura Bio Announces Chief Financial Officer Transition

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Zura Bio Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 6:30 AM EDT - 1 year ago

Zura Bio to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 6:30 AM EDT - 1 year ago

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 8, 2025, 7:00 AM EDT - 1 year ago

Zura Bio Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Zura Bio Earnings release: Q1 2025

May 8, 2025, 6:30 AM EDT - 1 year ago

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Zura Bio Proxy statement: Proxy Filing

Mar 25, 2025, 7:00 AM EDT - 1 year ago

Zura Bio Annual report: Q4 2024

Mar 25, 2025, 7:00 AM EDT - 1 year ago

Zura Bio Earnings release: Q4 2024

Mar 25, 2025, 6:30 AM EDT - 1 year ago

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

Mar 11, 2025, 1:40 PM EDT - 1 year ago

Zura Bio Transcript: Leerink Global Healthcare Conference 2025

Feb 24, 2025, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Dec 23, 2024, 6:30 AM EST - 1 year ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Dec 3, 2024, 9:00 AM EST - 1 year ago

Zura Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 6:30 AM EST - 1 year ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 12, 2024, 1:00 PM EST - 1 year ago

Zura Bio Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

Zura Bio Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Zura Bio Earnings release: Q3 2024

Nov 7, 2024, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Oct 30, 2024, 6:30 AM EDT - 1 year ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Sep 17, 2024, 2:30 PM EDT - 1 year ago

Zura Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 12:00 PM EDT - 1 year ago

Zura Bio Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Zura Bio Registration statement: Registration Filing

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Zura Bio Proxy statement: Proxy Filing

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Zura Bio Proxy statement: Proxy Filing

Sep 11, 2024, 11:30 AM EDT - 1 year ago

Zura Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Zura Bio Registration statement: Registration Filing

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Zura Bio Registration statement: Registration Filing

Sep 3, 2024, 6:00 AM EDT - 1 year ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Sep 3, 2024, 6:00 AM EDT - 1 year ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Aug 13, 2024, 9:30 AM EDT - 2 years ago

Zura Bio Quarterly report: Q2 2024

Aug 13, 2024, 9:30 AM EDT - 2 years ago

Zura Bio Earnings release: Q2 2024

Aug 13, 2024, 9:21 AM EDT - 2 years ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:05 PM EDT - 2 years ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 9, 2024, 4:05 PM EDT - 2 years ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Jul 12, 2024, 6:10 AM EDT - 2 years ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 6, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 3, 2024, 6:00 AM EDT - 2 years ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

May 29, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Participation in June Investor Conferences

May 24, 2024, 8:00 AM EDT - 2 years ago

Zura Bio Registration statement: Registration Filing

May 9, 2024, 7:00 AM EDT - 2 years ago

Zura Bio Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Zura Bio Earnings release: Q1 2024

May 9, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 18, 2024, 9:22 AM EDT - 2 years ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 8, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Announces Robert Lisicki as CEO and Director

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Zura Bio Annual report: Q4 2023

Mar 28, 2024, 5:00 PM EDT - 2 years ago

Zura Bio Earnings release: Q4 2023

Mar 28, 2024, 6:00 AM EDT - 2 years ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 4, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at March Conferences

Feb 2, 2024, 6:00 AM EST - 2 years ago

Zura Bio Announces Participation at February Investor Conferences

Jan 8, 2024, 6:00 AM EST - 2 years ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 3, 2024, 6:00 AM EST - 2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Dec 4, 2023, 6:00 AM EST - 2 years ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Nov 14, 2023, 6:00 AM EST - 2 years ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 13, 2023, 4:00 PM EST - 2 years ago

Zura Bio Quarterly report: Q3 2023

Nov 13, 2023, 4:00 PM EST - 2 years ago

Zura Bio Earnings release: Q3 2023

Nov 13, 2023, 6:30 AM EST - 2 years ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sep 12, 2023, 5:00 AM EDT - 3 years ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

MikeCaymanTrades Jun. 27 at 8:41 PM

$ZURA break from the long term trendline down. Overbought now but the weekly chart starting to turn up.

0 · Reply

StockScanners Jun. 27 at 5:56 PM

$ZURA keep watch if this holds above 5.19

0 · Reply

SannieVerraderlijk Jun. 27 at 10:44 AM

$ZURA Recent interview with CEO Sandeep Kulkarni. Readouts confirmed: HS Q4 26, SSC H1 27 https://www.youtube.com/watch?v=oKzZHBH_hfo

0 · Reply

topstockalerts Jun. 26 at 8:04 PM

$ZURA this is one of the cleaner charts on my screen today

0 · Reply

BanditQ Jun. 26 at 7:27 PM

$ZURA sold everything. +20% gain. Q4 is still a long way. Pretty sure we'll have another buying opportunity

0 · Reply

BanditQ Jun. 26 at 6:53 PM

$ZURA beautiful textbook chart

0 · Reply

deniz100 Jun. 26 at 4:37 PM

$ZURA Weak hand shake out. Loaded heavy above $4. Double digits will print here

0 · Reply

itrekntravel Jun. 26 at 3:42 PM

$ZURA hit my scans this am. what's moving it ~ anyone know?

1 · Reply

SannieVerraderlijk Jun. 26 at 3:15 PM

$ZURA

0 · Reply

BanditQ Jun. 26 at 2:45 PM

$ZURA hell yeah

0 · Reply

SannieVerraderlijk Jun. 25 at 9:42 AM

$ZURA If no delay, test 4.65 resistance, bounce on 4.00 support, run to 6.50 pre-data?

2 · Reply

StockScanners Jun. 23 at 3:29 AM

$ZURA keep watch if this holds above 4.11

0 · Reply

stu4 Jun. 2 at 1:05 AM

$ABVX $CADL $ZURA Maybe MAIA as well

0 · Reply

stu4 Jun. 2 at 1:05 AM

$ABVX $CADL $ZURA Learn to pick better bios ! Bet you own Srpt as well, lol

0 · Reply

Astrobro Jun. 1 at 9:09 PM

$CADL The only green Candel bio in my account 🥲$NKTR $ABVX $ZURA have not been kind to me

0 · Reply

SannieVerraderlijk May. 27 at 8:37 AM

$ZURA Doubled position at 4.20, with room to add 3.50/3.20 and below if it goes there

0 · Reply

monoksop May. 19 at 11:32 PM

$ZURA Added here

0 · Reply

focafoca99 May. 7 at 12:14 PM

$ZURA says it released its first‑quarter 2026 financial results via a press release.

0 · Reply

SuperGreenToday May. 4 at 3:36 PM

$ZURA Share Price: $5.47 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.68 – $0.83 Potential Upside: 69% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Breck100 Apr. 6 at 3:58 PM

$ZURA Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Apr 01, 2026, 07:37 AM Piper Sandler Reaffirms Their Buy Rating on Zura Bio (ZURA) Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Zura Bio today and set a price target of $26.00.

0 · Reply

Market Cap	430.76M
Revenue (ttm)	0.00
Net Income (ttm)	-99.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,625,400
Avg Vol	1,015,786
Day's Range	N/A - N/A
Shares Out	94.88M
Stochastic %K	95%
Beta	0.03
Analysts	Strong Sell
Price Target	$16.00